论文部分内容阅读
目的比较培美曲塞与多西他塞联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2009年2月—2010年8月绵阳市盐亭县肿瘤医院胸外科收治的晚期NSCLC患者108例,随机分为PC方案组和DP方案组,每组54例。PC方案组采用培美曲塞联合顺铂化疗方案,DP方案组采用多西他塞联合顺铂化疗方案;3周为1个化疗周期,两组患者均至少治疗2个化疗周期。比较两组患者化疗结束后2周临床疗效、无进展生存期及化疗期间毒副作用发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。PC方案组患者无进展生存期长于DP方案组(P<0.05)。两组患者白细胞计数减少、中性粒细胞计数减少、血小板计数减少、血红蛋白减少、恶心呕吐、肝功能损伤及肾功能损伤程度比较,差异无统计学意义(P>0.05);PC方案组患者脱发程度轻于DP方案组(P<0.05)。结论培美曲塞与多西他塞联合顺铂治疗晚期NSCLC的临床疗效相似,但培美曲塞联合顺铂化疗方案可更有效地延长患者无进展生存期,减轻脱发程度。
Objective To compare the clinical efficacy of pemetrexed and docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 108 patients with advanced NSCLC admitted to Yanting Tumor Hospital of Mianyang City from February 2009 to August 2010 were randomly divided into a PC group and a DP group, with 54 cases in each group. PC regimen with pemetrexed combined with cisplatin chemotherapy, DP regimen with docetaxel combined with cisplatin chemotherapy; 3 weeks for a chemotherapy cycle, two groups of patients were treated for at least two cycles of chemotherapy. The clinical efficacy, progression-free survival and side effects during chemotherapy were compared between the two groups after 2 weeks of chemotherapy. Results There was no significant difference in clinical efficacy between the two groups (P> 0.05). Progression-free survival in patients in the PC regimen group was longer than in the DP regimen group (P <0.05). There were no significant differences in the number of white blood cell count, neutrophil count, platelet count, hemoglobin, nausea and vomiting, liver injury and renal dysfunction between the two groups (P> 0.05) To a lesser degree, DP regimen group (P <0.05). Conclusion Pemetrexed and docetaxel combined with cisplatin in the treatment of advanced NSCLC clinical efficacy similar, but pemetrexed combined with cisplatin chemotherapy can be more effective in patients with progression-free survival and reduce the degree of hair loss.